153587-11-2

Basic information

• Product Name: 3-(DIFLUOROMETHOXY)-4-METHOXYBENZALDEHYDE
• Synonyms: TIMTEC-BB SBB011023;ASINEX-REAG BAS 12541203;3-(DIFLUOROMETHOXY)-4-METHOXYBENZALDEHYDE
• CAS NO: 153587-11-2
• Molecular Formula: C₉H₈F₂O₃
• Molecular Weight: 202.15
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 153587-11-2.mol

Chemical Properties

• Boiling Point: 269.9±35.0 °C(Predicted)
• Appearance: /
• Density: 1.260±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 3-(DIFLUOROMETHOXY)-4-METHOXYBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(DIFLUOROMETHOXY)-4-METHOXYBENZALDEHYDE(153587-11-2)
• EPA Substance Registry System: 3-(DIFLUOROMETHOXY)-4-METHOXYBENZALDEHYDE(153587-11-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 153587-11-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(Difluoromethoxy)-4-methoxybenzaldehyde is used as an impurity in the production of the antiasthmatic drug Roflumilast (R639700). Its presence in the drug is significant due to its potential effects on the drug's efficacy and safety. As an impurity, it is essential to monitor and control its levels to ensure the quality and performance of the final drug product.

Upstream product

• 621-59-0 isovanillin 
• 75-45-6 Chlorodifluoromethane 
• 56-93-9 benzyltrimethylammonium chloride 
• 1895-39-2 sodium chlorodifluoroacetate 
• 383-62-0 ethyl 2-chloro-2,2-difluoroacetate 

Downstream Products

• 162401-65-2 4-difluoromethoxy-3-methoxybenzoic acid 
• 1223714-21-3 2-difluoromethoxy-1-methoxy-4-((E)-2-nitro-vinyl)-benzene 
• 194735-70-1 3-(1,1-difluoro-methoxy)-4-methoxy-ω-nitrostyrene 
• 1259022-91-7 (E)-2-[3-(4-methoxy-3-(difluoromethoxy)phenyl)-1-oxo-2-propenyl]benzoic acid 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY

The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non- alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound

Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same

The present technology relates to compounds of Formulas I-VI and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also increase HDL-C, lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.

PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES

The invention relates to novel phenethylamide derivatives and their heterocyclic analogues of formula (I), wherein A, B, R1, R2 and R3 are as described in the application, and to the use of such compounds, or of pharmaceut

CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS

The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL- cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated potein kinase.

NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to novel heterocyclic compounds that inhibit phosphodiesterase type 4 (PDE 4). The compounds are useful for treating inflammatory conditions, diseases of the central nervous systems and insulin resistant diabetes.

Phenanthridines

Compounds of formula (I), where R1, R2, R3, R31, R4, R5, R51 and R6 have the meanings given in the description, are new active bronchial therapeutic agents.

FLUOROALKOXY-SUBSTITUTED BENZAMIDES AND THEIR USE AS CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS

Compounds of formula (I), in which one of the substituents R1 or R2 stands for hydrogen, 1-6C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, benzyloxy or totally or partially fluorine-substituted 1-4C-alkoxy, and the other stands for totally or partially fluorine-substituted 1-4C-alkoxy, and R3 stands for phenyl, pyridyl, R31, R32 and R33-substituted phenyl or R34, R35, R36 and R37-substituted pyridyl, in which R31 stands for hydroxy, halogen, cyano, carboxyl, trifluoromethyl 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, 1-4C-alkylcarbonyloxy, amino, mono- or di-1-4C-atkylamino or 1-4C-alkylcarbonylamino; R32 stands for hydrogen, hydroxy, halogen, amino, trifluoromethyl, 1-4C-alkyl or 1-4C-alkoxy; R33 stands for hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy; R34 stands for hydroxy, halogen, cyano, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl or amino; R35 stands for hydrogen, halogen, amino or 1-4C-alkyl; R36 stands for hydrogen or halogen; and R37 stands for hydrogen or halogen. These compounds constitute new effective bronchotherapeutic drugs

Compounds useful for treating allergic or inflammatory diseases

Novel cyclohexanes of Formulas (I) and (II) STR1 are described herein. They inhibit the production of Tumor Necrosis Factor and are useful in the treatment of disease states mediated or exacerbated by TNF production; these compounds are also useful in the mediation or inhibition of enzymatic or catalytic activity of phosphodiesterase V.